Adenoviral-based COVID-19 vaccines may up short-term CV risk
Aug 23, 2022
An increased incidence of myocardial infarction and pulmonary embolism were seen in the second week after first dose of Oxford-AstraZeneca vaccine.
COVID-19 falls from America’s No. 1 killer to No. 7 by June
Jul 01, 2021
COVID-19 deaths have fallen sharply as vaccination rates have surged in recent months.
Small CV impact seen when replacing salt with low-sodium salt substitute
Aug 24, 2022
The small effects of LSSS versus regular salt on cardiovascular health in adults may be important when implemented at the population level
Accelerated trajectory of CV risk predicts dementia risk
Apr 21, 2022
Those with an accelerated versus stable cardiovascular risk trajectory have an increased risk for memory decline.
Low exercise may amplify link between poor sleep, mortality risk
Jun 30, 2021
The highest risks for all-cause, total CVD, total cancer, lung cancer mortality were seen in the no moderate-to-vigorous physical activity/poor sleep group.
Risks for diabetes, CVD up in acute, postacute COVID-19 phases
Jul 20, 2022
However, from 13 to 52 weeks after COVID-19, no increase was seen for diabetes mellitus or cardiovascular disease.
Hypertension linked to hospitalization for omicron in vaccinated persons
Aug 09, 2022
The findings were seen among individuals who received at least three mRNA vaccine doses and in whom COVID-19 subsequently was diagnosed during omicron surge.
BP genetic risk score linked to risk for CV events in type 2 diabetes
Apr 04, 2022
Each standard deviation increase in BP polygenic risk score was linked to a 12% increased hazard of adverse cardiovascular events.
Prior statin use linked to reduced risk for death in COVID-19
Jul 21, 2021
The risk for death was significantly reduced with prior statin and/or antihypertensive use among those with a history of cardiovascular and/or hypertension.
Monoclonal antibody therapy may cut COVID-19 hospitalizations
Aug 31, 2021
Lower hospitalization rates were seen at 14, 21 and 28 days for high-risk patients with mild-to-moderate COVID-19 who received casirivimab-imdevimab.